Use of Perirectal Hyaluronic Acid Spacer Prior to Radiotherapy in a Pediatric Patient With Bladder Rhabdomyosarcoma: A Case Report

Urology. 2023 Nov:181:136-140. doi: 10.1016/j.urology.2023.06.018. Epub 2023 Jul 14.

Abstract

Rhabdomyosarcoma (RMS) treatment involves surgery, chemotherapy, and radiotherapy. A radioprotective space between the bladder/prostate and rectum reduces postradiation complications, as reported in adult patients. Describe pediatric preradiotherapy perirectal hyaluronic acid (HA) spacer injection for bladder/prostate RMS. We present a case of a 17-month-old male with bladder/prostate RMS. Before radiotherapy, an HA spacer was injected peri-rectally. Under general anesthesia, a transrectal ultrasound was positioned and 1mL of HA spacer was injected into the perirectal space. No complications were reported at 6-month follow-up. This is the first report of pre-radiation therapy spacer injection for pediatric bladder/prostate RMS.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Child
  • Humans
  • Hyaluronic Acid / therapeutic use
  • Infant
  • Male
  • Pelvic Neoplasms*
  • Prostatic Neoplasms*
  • Rhabdomyosarcoma* / radiotherapy
  • Rhabdomyosarcoma, Embryonal*
  • Urinary Bladder / diagnostic imaging
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / radiotherapy

Substances

  • Hyaluronic Acid